IL6 −174G>C gene polymorphism in psoriasis: Focus on treatment efficacy

Abstract

Interleukin-6 (IL-6) is implicated in the pathogenesis of psoriasis as well as in its treatment efficacy. The aim of this study of 406 psoriasis patients and 203 healthy controls was to evaluate the association between the IL6 À174G>C (rs1800795) polymorphism and psoriasis susceptibility, as well as treatment efficacy. The frequency of genotype GG (33.7% vs. 20.7%; p = 0.00022; OR = 0.51, 95% confidence interval 0.34-0.76) and of allele G (56.2% vs. 46.8%; p = 0.0023) was significantly higher in the psoriasis group compared to controls. No polymorphism variants were associated with better response to topical or combined topical/ narrow-band ultraviolet B (NB-UVB) treatment. We conclude that the IL6 À174G>C polymorphism can be a marker of susceptibility to psoriasis, with an almost 2-fold increased risk of the disease in individuals carrying the GG genotype; however, it was not associated with treatment response to topical and/or NB-UVB therapy.http://dx.

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine

“…There have been several studies searching for an association between genetic polymorphisms and the response to phototherapy in many different genes and populations: PPARγ2 [32], IL-12B, IL-17A, IL-23R, IL-23A [33], HLA-C [34], IL-17F [35], IL-6 [36], and MC1R [37], but all of them showed no effect on response.…”